从温病学理论探讨论治肿瘤分子靶向药物相关皮肤毒性

中华养生保健 ›› 2024, Vol. 42 ›› Issue (7): 57-59.

从温病学理论探讨论治肿瘤分子靶向药物相关皮肤毒性

胡新舟¹, 姜博¹, 吴珍珍¹, 朱国庆², 周义浪², 田杰^3,*

1.贵州中医药大学,贵州贵阳,550002;
2.贵州中医药大学第二附属医院肿瘤科,贵州贵阳,550003;
3.贵州中医药大学第一附属医院肿瘤科,贵州贵阳,550001

出版日期:2024-04-01 发布日期:2024-03-20
通讯作者: ^*田杰,E-mail：33786540@qq.com。
作者简介:胡新舟（1997—）,女,汉族,籍贯：贵州省毕节市,硕士研究生在读,研究方向：中西医结合防治恶性肿瘤。
基金资助:
黔科合成果[-LC（2022）035]; 贵州省普通高等学校青年科技人才成长项目[黔教合KY字(2022)270号]

Study on Skin Toxicity Related to Molecular Targeted Drugs for Treating Tumor from Februarial Theory

HU Xin-zhou¹, JIANG Bo¹, WU Zhen-zhen¹, ZHU Guo-qing², ZHOU Yi-lang², TIAN Jie^3,*

1. School of Chinese Medicine, Guizhou University of Chinese Medicine, Guiyang Guizhou 550002, China;
2. The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang Guizhou 550003, China;
3. The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang Guizhou 550002, China

Online:2024-04-01 Published:2024-03-20

摘要/Abstract

摘要： 分子靶向药物已成为许多肿瘤治疗的重要药物,然而皮肤毒性是运用靶向药物发挥抗肿瘤疗效时出现的主要不良反应,严重影响肿瘤患者治疗期间的生活质量,因此,缓解其不良反应对于提高患者的治疗依从性、生活质量甚为重要。从皮肤毒性临床表现及发生演变规律看,均符合温热病演变规律。采用温病学卫气营血辨证论治体系进行综合诊治,把“透法”思维贯穿在诊治全过程,取得较好的临床疗效,为靶向药物皮肤毒性的治疗提供全程中医药干预治疗思路并提高肿瘤患者生活质量。

关键词: 分子靶向药物, 皮肤毒性, 卫气营血, 透法

Abstract: Molecular targeted drugs have become an important drug in the treatment of many tumors. However, skin toxicity is the main toxic side effect that occurs when targeted drugs exert anti-tumor efficacy, which seriously affects the quality of life of tumor patients during treatment. Therefore, alleviating the adverse reactions is particularly important for improving the treatment tolerance and quality of life of patients. From the clinical manifestation and evolution of skin toxicity, it is consistent with the evolution of warm and heat disease. The comprehensive diagnosis and treatment system of Wei Qi Ying Blood syndrome differentiation in febrile disease was adopted to carry out the "transparent method" thinking throughout the whole process of diagnosis and treatment, and achieved good clinical efficacy, providing the whole TCM intervention treatment idea for the treatment of targeted drug skin toxicity and improving the quality of life of tumor patients.

Key words: molecular targeted drugs, skin toxicity, Wei Qi Ying Blood, translucent

中图分类号:

R273

胡新舟, 姜博, 吴珍珍, 朱国庆, 周义浪, 田杰. 从温病学理论探讨论治肿瘤分子靶向药物相关皮肤毒性[J]. 中华养生保健, 2024, 42(7): 57-59.

HU Xin-zhou, JIANG Bo, WU Zhen-zhen, ZHU Guo-qing, ZHOU Yi-lang, TIAN Jie. Study on Skin Toxicity Related to Molecular Targeted Drugs for Treating Tumor from Februarial Theory[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(7): 57-59.

参考文献

[1] 刘颖,谢言,王新天.分子靶向抗肿瘤药物的毒性研究[J].医学信息,2021,34(14): 48-50.
[2] AN D, CHU W G, DAI F.Analysis of 125 cases of adverse reactions of bevacizumab injection[J]. Chin J Hosp Pharm(中国医院药学杂志),2013,33(9):749-751.
[3] SINGH A P, SHIN Y G, SHAH D K.Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development[J]. Pharm R, 2015,32:3508-3525.
[4] CHULAROJANAMONTRI L, TUCHINDA P,LIKITWATTANANURAK C,et al.Cutaneous toxicities of epidermal growth factor recep-tor inhibitors: a prospective study in 60 Asian patients[J]. Asian Pac J Allergy Immunol,2019,58(7):47-55.
[5] GUTZMER R, WOLLENBERG A, UGUREL S, et al.Cutaneousside effects of new antitumor drugs; clinical features and manage-ment[J]. Deut –sches rzteblatt International,2012,109(8):133.
[6] WAGNER L I,LACOUTURE M E.Dermatologic toxicities as、sociated with EGFR inhibitors:the clinical psychologists perspective. Impact on health-related quality of life and im、plications for clinical management of psychological sequelae[J]. Oncology,2007,21(5):34-36.
[7] LLOVET J M, MONTAL R,SIA D,et al.Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol,2018,15(10):599-616.
[8] PINTO C, BARONE CA, GIROLOMONI G,et al.Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy[J]. The Oncologist,2011,16(2):228-238.
[9] MACDONALD J B, M ACDONALD B,GOLITZ L E,et al. Cutane-ous adverse effects of targeted therapies[J]. J Am Acad Dermatol,2015,72(2):203-218.
[10] REVES-HABITO C M, ROH E K. Cutaneous reactions to che-motherapeutic drugs and targeted therapies for cancer[J]. Journalof the American Academy of Dermatology,2014,71(2):203-215.
[11] 张心悦. 表皮生长因子受体拮抗剂相关皮肤不良反应的变化规律及中医证型变化的临床研究[D].北京:北京中医药大学,2014.
[12] 蒋梅,纪丽芝.从温病学斑疹论治探析肿瘤分子靶向药物相关皮肤毒性的中医药应对策略[J].中医肿瘤学杂志,2019,1(5):18-22.
[13] 张小瑞,赵远红.非小细胞肺癌靶向药物相关皮肤毒性反应的中医辨治[J].中医杂志,2015,56(12):1065-1066.
[14] 戚益铭,徐国暑.从温病“透法”探讨表皮生长因子受体酪氨酸激酶抑制剂皮肤毒性的辨治思路[J].浙江中医杂志,2018,53(8):578-579.
[15] 侯天将,由凤鸣,祝捷,等.从“清、透、滋”三治则论治靶向药物皮肤毒性[J].四川中医,2017,35(10):28-30.
[16] 吴若云. 从温病卫气营血理论探讨急性皮肤病的病机与治法[J].光明中医,2020,35(14):2138-2140.
[17] 肖战说,崔炳南.《湿病条辨》斑疹理论初探[J].安徽中医药大学学报,2018,37(6):8-10.
[18] 吴若云. 从温病卫气营血理论探讨急性皮肤病的病机与治法[J].光明中医,2020,35(14):2138-2140.
[19] 余国芳. EGFRIs 相关皮肤毒性中医病因病机及辨证治疗分析[D].广州:广州中医药大学,2009.
[20] 余国芳,林丽珠.林丽珠辨治表皮生长因子受体抑制剂相关皮渗的经验探析[J].世界科学技术(中医药现代化),2009,11(5):758-763.